Дисертації з теми "RETROVIRAL PROTEASE"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-33 дисертацій для дослідження на тему "RETROVIRAL PROTEASE".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте дисертації для різних дисциплін та оформлюйте правильно вашу бібліографію.
Peng, Kah Whye. "Protease-activatable targeted retroviral vectors." Thesis, University of Cambridge, 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.624668.
Повний текст джерелаGarner, Joanne Clare. "Site directed mutagenesis, autoprocessing and inhibitor studies on the retroviral protease of the human immunodeficiency virus type-1." Thesis, University of Southampton, 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.302318.
Повний текст джерелаMuller, Natalie Guida. "Identificação de epitopos da protease de HIV-1 alvos de respostas de células T CD4+ em pacientes infectados pelo HIV-1." Universidade de São Paulo, 2009. http://www.teses.usp.br/teses/disponiveis/5/5146/tde-05032010-170301/.
Повний текст джерелаIntroduction: A significant proportion of protease inhibitor (PI)-treated HIV-1 infected (HIV-1+) patients develop resistance mutations. Recent studies have shown that CD8+ T cells from HIV-1 patients can recognize antiretroviral drug-induced mutant Pol epitopes. No HIV-1 protease CD4 epitopes are described in the Los Alamos database. Aims: Given that the protease of HIV-1 is a target of antiretroviral therapy and this pressure may lead to the selection of mutations, we investigated whether PI-induced mutations affect the recognition of HIV-1 protease epitopes by CD4 + T cells in PI-treated patients. We investigated the recognition of three protease regions predicted to harbor CD4+ T cell epitopes as well as PI-induced mutations by CD4+ T cells of PI-treated HIV-1+ patients. Methods: Forty PI-treated HIV-1+ patients were included (30 undergoing Lopinavir/ritonavir, 9 undergoing Atazanavir/ritonavir and 1 undergoing exclusively Atazanavir treatment). For each patients, the endogenous HIV-1 protease sequence, viral genotype and HLA class II typing were determined. We used the TEPITOPE algorithm to select promiscuous, multiple HLA-DR-binding peptides encoding 3 regions of HIV-1 HXB2 strain protease (HXB2 4-23, 45-64, and 76-95) and 32 additional peptides contained in the same regions, but encompassing the most frequent PI-induced mutations in Brazil. The 35 peptides were thus synthesized. Proliferative responses of CD4+ and CD8+ T cells against peptides were determined by the CFSE dilution assay. HLA class II binding assays were made to confirm the promiscuity of these peptides and evaluate their ability to bind the HLA molecules carried by each patient. Results: All tested peptides were recognized by at least one patient and proliferative responses of CD4+ and CD8+ T cells against at least one HIV-1 protease peptide were found in 78% and 75% patients, respectively. The third region (Protease 76-95) was the most frequently recognized. By comparing T-cell responses to HIV-1 endogenous protease sequences, we found that most patients failed to recognize identical peptides of those sequences, but recognized different variant peptides of the same region. Only seven patients responded to endogenous sequences. We found that several endogenous peptides that failed to be recognized showed no binding to the HLA alleles carried by that given patient, suggesting that mutations selected by immune pressure have led to escape of antigen presentation, as well as direct escape of the CD4+ T cell response. Alternatively, it could have been due to the presence of a different replicating virus in the plasma-since we only obtained proviral sequences. Conclusion: Wild-type and mutant HIV-1 protease epitopes recognized by CD4+ T cells were identified. We also found that most patients failed to recognize their endogenous protease sequences, while they recognized variant sequences. The recognition of non-endogenous sequences could hypothetically be a consequence of targeting a minor HIV-1 population; HERV protease, that contains regions of similarity with HIV-1 protease; or HIV-1 sequences present only in viremic partners. The failure to recognize endogenous sequences is most likely due to immune escape, either at the level of presentation or direct T cell recognition. This may have a pathophysiological consequence on evasion of T cell responses against protease and the fact that it has been considered traditionally a poorly antigenic HIV-1 protein.
Junaid, Muhammad. "Studies of Retroviral Reverse Transcriptase and Flaviviral Protease Enzymes as Antiviral Drug Targets : Applications in Antiviral Drug Discovery & Therapy." Doctoral thesis, Uppsala universitet, Institutionen för farmaceutisk biovetenskap, 2012. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-173504.
Повний текст джерелаHinks, John Andrew. "Studies of retroviral proteases." Thesis, University College London (University of London), 2005. http://discovery.ucl.ac.uk/1445580/.
Повний текст джерелаLeblanc, Pascal. "Retrovirus d'invertebres : zam un nouveau candidat chez drosophila melanogaster." Clermont-Ferrand 1, 1998. http://www.theses.fr/1998CLF1MM12.
Повний текст джерелаGESSNER, JEAN-YVES. "La proteine de la nucleocapside du retrovirus vih-1." Strasbourg 1, 1992. http://www.theses.fr/1992STR15031.
Повний текст джерелаSchucht, Roland. "Entwicklung von flexiblen Zelllinien für die Produktion rekombinanter Proteine und Retroviren." kostenfrei, 2006. http://www.digibib.tu-bs.de/?docid=00014003.
Повний текст джерелаMorphet, Marilynn Norma. "Method for identification of effective first-line treatment for HAART naïve HIV/AIDS patients." Thesis, Queensland University of Technology, 2002.
Знайти повний текст джерелаMénard, Armelle. "Purification, activité et inhibition de la protéase du rétrovirus BLV : un modèle d'étude pour celle du HTLV-1." Bordeaux 2, 1994. http://www.theses.fr/1993BOR28278.
Повний текст джерелаGUYONNET, FRANCK. "La proteine p27 de groupe des retrovirus aviaires : production d'anticorps monoclonaux et etude de l'antigenicite." Tours, 1993. http://www.theses.fr/1993TOUR4007.
Повний текст джерелаCartellieri, Marc. "Untersuchungen zum Gag- und Pol-Protein des Prototypischen Foamyvirus (PFV)." Doctoral thesis, Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2006. http://nbn-resolving.de/urn:nbn:de:swb:14-1149777659789-93621.
Повний текст джерелаTeysset, Laure. "La proteine d'enveloppe du retrovirus gypsy : etude de son role et de sa fonction chez drosophila melanogaster." Paris 7, 1998. http://www.theses.fr/1998PA077155.
Повний текст джерелаTrentin, Bernadette. "Transcriptase inverse du HTLV-I : expression, structure et rôle dans l'infectiosité/." Bordeaux 2, 1999. http://www.theses.fr/1999BOR28640.
Повний текст джерелаCartellieri, Marc. "Untersuchungen zum Gag- und Pol-Protein des Prototypischen Foamyvirus (PFV)." Doctoral thesis, Technische Universität Dresden, 2005. https://tud.qucosa.de/id/qucosa%3A24712.
Повний текст джерелаCunha, Joel da. "Estudo da atividade e polimorfismos da Paraoxonase-1 em indivíduos infectados pelo vírus da imunodeficiência humana tipo-1 (HIV-1) tratados com inibidores de protease." Universidade de São Paulo, 2012. http://www.teses.usp.br/teses/disponiveis/5/5146/tde-10052013-095130/.
Повний текст джерелаThe enzyme Paraoxonase-1 (PON1) has paraoxonase (PON), arylesterase (ARE) and lactonase activities, among others. It is the most studied member of PON family which is composed of PON1, PON2 and PON3. It is suggested that all members acts by inhibiting the peroxidation of lipid molecules as the low-density lipoprotein (LDL) and high-density lipoprotein (HDL), characterizing a potential anti-atherogenic effect. The PON1 gene has two mainly polymorphic sites, with an exchange of Gln192Arg (Q/R) and Met55Leu (L/M), which are associated with differences in activity and serum concentrations of the enzyme. In turn, seropositive individuals for HIV-1 show changes in lipid metabolism, which could be associated with changes in the activity of PON1 and highly active antiretroviral therapy (HAART) with protease inhibitors (PI). The aim of this study was to determinate the serum PON and ARE activities of PON1, the allele frequencies of PON1 192QR and PON1 55LM genetic polymorphisms and evaluate the correlation between these parameters and lipid abnormalities in seropositive patients for HIV-1 treated with IP. In the period from September 2009 until June 2012, 174 seropositive individuals and 46 soronegative individuals for HIV-1 were studied. We performed PON1 192QR and 55LM genotyping by PCR-RFLP. Serum activities PON and ARE of PON1 were evaluated by spectrophotometry using paraoxon and phenylacetate, respectively, as substrates. The HIV-1-RNA was quantified by the NASBA method, and lymphocytes T-CD4+ and T-CD8+, by flow cytometry. Serum levels of total cholesterol, HDL, LDL, triglycerides (TG), apoA1 and ApoB100 were determined. IgG anti-oxLDL antibodies were quantified by ELISA. The serum PON1 activity was lower in the seropositive group, p<0.05, however, ARE activity did not differ between groups, p>0.05. Both activities had no relation with the PON1 192QR and PON1 55LM genotype, and these individuals showed an allele frequency similar to the seronegative group. Serum levels of TG were higher in groups of HIV-positive with HAART, p<0.05, while the IP-treated group showed serum levels of HDL and ApoA1 lower than other groups, p <0.05. Serum levels of ApoB100, IgG anti-oxLDL antibodies, and atherogenic risk indices were higher in the group treated with PI, p<0.05. It was concluded that individuals HIV-1-infected showed changes in lipid metabolism, especially in those treated with IP, which additionally showed a higher rate of atherogenic risk and higher levels of IgG anti-oxLDL antibodies. These changes did not correlated with PON1 192QR and 55LM polymorphisms and demonstrated that the activity of PON1enzyme is decreased in individuals seropositive for HIV-1
Kontijevskis, Aleksejs. "Modeling the Interaction Space of Biological Macromolecules: A Proteochemometric Approach : Applications for Drug Discovery and Development." Doctoral thesis, Uppsala : Acta Universitatis Upsaliensis, 2008. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-8916.
Повний текст джерелаDörrschuck, Eva Amarant [Verfasser], and Manfred J. [Akademischer Betreuer] Schmitt. "Molekularbiologische Untersuchungen zur Interaktion der antiretroviral wirkenden porzinen und humanen A3-Proteine mit porzinen endogenen Retroviren (PERV) und Charakterisierung des porzinen A3-Genlokus / Eva Amarant Dörrschuck. Betreuer: Manfred J. Schmitt." Saarbrücken : Saarländische Universitäts- und Landesbibliothek, 2011. http://d-nb.info/1051095344/34.
Повний текст джерелаVoisset, Cécile. "Étude de la nouvelle famille de rétrovirus endogènes humains HERV-W dans un contexte normal et dans un contexte pathologique (sclérose en plaques)." Lyon 1, 1999. http://www.theses.fr/1999LYO1T132.
Повний текст джерелаWECKER, KARINE. "Etudes structurales par resonance magnetique homonucleaire et heteronucleaire, et par modelisation moleculaire de la proteine de regulation vpr du retrovirus vih-1, et de deux de ses fragments, vpr(1-51) et vpr(52-96)." Paris 6, 2000. http://www.theses.fr/2000PA066476.
Повний текст джерелаLegrand, Alain. "Liposomes cibles et vecteurs retroviraux pour le transfert et l'expression du gene de la preproinsuline i de rat dans des cellules eucaryotes." Orléans, 1987. http://www.theses.fr/1987ORLE2011.
Повний текст джерелаGillcrist, Marion. "HIV, cardiovascular disease, anti-retroviral resistance: the issue with protease inhibitors and a need for alternatives." Thesis, 2020. https://hdl.handle.net/2144/41243.
Повний текст джерелаBiswas, Iman. "Structural and functional studies on DNA damage inducible protein 1 (Ddi1) from protozoa." Thesis, 2020. https://etd.iisc.ac.in/handle/2005/4838.
Повний текст джерелаZiregbe, Elohor. "A comparison of the effectiveness of protease inhibitor-based highly active anti-retroviral treatment regiments in Trinidad and Tobago." Diss., 2013. http://hdl.handle.net/10500/14199.
Повний текст джерелаHealth Studies
M. A. (Public Health)
Finger, Carsten [Verfasser]. "Entwicklung retroviraler scFv-display-Bibliotheken und Expression therapeutischer Proteine durch replikationskompetente retrovirale Vektoren / von Carsten Finger." 2006. http://d-nb.info/980649730/34.
Повний текст джерелаKumar, Sushant. "Structural Studies on DNA Damage Inducible Protein 1 (Ddi1) of Leishmania and the Rotavirus Nonstructural Protein NSP4." Thesis, 2016. http://etd.iisc.ac.in/handle/2005/3018.
Повний текст джерелаKumar, Sushant. "Structural Studies on DNA Damage Inducible Protein 1 (Ddi1) of Leishmania and the Rotavirus Nonstructural Protein NSP4." Thesis, 2016. http://hdl.handle.net/2005/3018.
Повний текст джерелаCruz, Rui Gonçalo Batista Mamede da. "New retroviral-like membrane-associated aspartic proteases from rickettsiae: biochemical characterization and specificity profiling." Doctoral thesis, 2015. http://hdl.handle.net/10316/26477.
Повний текст джерелаOs membros do género Rickettsia são bactérias intracelulares obrigatórias do tipo gram-negativas, cuja transmissão a mamíferos pode ocorrer através de vetores artrópodes como carraças, pulgas ou piolhos. Entre as várias espécies identificadas, muitas são patogénicas para o Homem causando doenças infeciosas agudas das quais se destacam o tifo epidémico (Rickettsia prowazekii), a febre maculosa das montanhas rochosas (Rickettsia rickettsii) e a febre escaro-nodular (Rickettsia conorii). A elevada patogenicidade e o caráter emergente destas doenças, associados à inexistência de vacinas eficazes para a sua prevenção, reforçam inequivocamente a necessidade de identificar novos fatores proteicos para o desenvolvimento de terapêuticas inovadoras. Neste sentido, tem-se assistido nas últimas décadas a avanços significativos na compreensão dos mecanismos de patogénese e de resposta imunitária às rickettsioses. Contudo, a validação da função biológica de genes de Rickettsia tem sido amplamente limitada pela natureza estritamente intracelular destes organismos que dificulta a sua manipulação. Por conseguinte, a comparação entre os múltiplos genomas disponíveis de Rickettsia tem revelado ser o método mais expedito para a identificação de novos fatores proteicos potencialmente implicados na patogenicidade destes micro-organismos. Este trabalho descreve a identificação e caracterização de uma nova protease membranar do tipo retropepsina, altamente conservada em 55 genomas de Rickettsia. Apesar da baixa similaridade na sequência de aminoácidos relativamente a outras retropepsinas, demonstrámos que a proteína codificada pelo gene homólogo RC1339 de R. conorii Malish 7, designada por APRc para protease aspártica de Rickettsia conorii, é uma enzima ativa com propriedades altamente reminiscentes desta família de proteases aspárticas. Entre outras, destacam-se a atividade autolítica comprometida pela mutação do aspartato catalítico, a acumulação na forma dimérica, uma atividade ótima a pH de 6 e a inibição por inibidores específicos da protease do vírus da imunodeficiência humana do tipo 1. Além disso, utilizando uma abordagem de mapeamento de especificidade de alto débito, foi possível confirmar que os determinantes de especificidade da APRc são semelhantes aos de outras proteases aspárticas de ambos os tipos, retropepsina e pepsina. Neste trabalho, demonstrámos também que o gene codificante da APRc é transcrito e traduzido em pelo menos duas espécies patogénicas de Rickettsia (R. conorii e R. rickettsii), e que esta proteína é integrada na membrana externa de ambas. Ao explorar as potenciais funções biológicas da APRc, verificámos que esta protease catalisa o processamento in vitro de dois membros da família das proteínas autotransportadoras envolvidas na adesão e invasão de Rickettsia: Sca5/rOmpB e Sca0/rOmpA. Estes resultados apontam assim para a participação da APRc numa via proteolítica relevante para a virulência destes micro-organismos, surgindo esta protease como um alvo interessante para a intervenção terapêutica contra as rickettsioses. Por fim, ao demonstrar que a APRc é um novo membro da família das proteases aspárticas do tipo retropepsina, provamos simultaneamente que estas enzimas estão efetivamente presentes em bactérias gram-negativas intracelulares, pelo que poderão representar uma forma ancestral desta classe de proteases.
Members of the genus Rickettsia are obligate intracellular, gram-negative, arthropod-borne pathogens of humans and other mammals, causing severe infections including epidemic typhus (Rickettsia prowazekii), Rocky Mountain spotted fever (Rickettsia rickettsii), and Mediterranean spotted fever (Rickettsia conorii). The life-threatening character of diseases caused by many Rickettsia spp. and the lack of reliable protective vaccine against rickettsioses strengthens the importance of identifying new protein factors for the potential development of innovative therapeutic tools. However, progress in correlating rickettsial genes and gene functions has been greatly hampered by the intrinsic difficulty in working with these obligate intracellular bacteria, despite the increasing insights into the mechanisms of pathogenesis of and the immune response to rickettsioses. Therefore, comparison of the multiple available genomes of Rickettsia is proving to be the most practical method to identify new factors that may play a role in pathogenicity. The present work reports the identification and characterization of a novel membrane-embedded retropepsin-like homologue, highly conserved in 55 Rickettsia genomes. Using R. conorii Malish 7 gene homologue RC1339 as our working model we demonstrate that, despite the low overall sequence similarity to retropepsins, the gene product of RC1339 APRc (for Aspartic Protease from Rickettsia conorii) is an active enzyme with features highly reminiscent of this family of aspartic proteases, such as autolytic activity impaired by mutation of the catalytic aspartate, accumulation in the dimeric form, optimal activity at pH 6, and inhibition by specific HIV-1 protease inhibitors. Moreover, specificity preferences determined by a high-throughput profiling approach confirmed common preferences between this novel rickettsial enzyme and other aspartic proteases, both retropepsin and pepsin-like enzymes. Additionally, we have also shown that APRc is transcribed and translated by at least two pathogenic rickettsial species, R. conorii and R. rickettsii, and is integrated into the outer membrane of both species. By further exploring one of its putative biological roles, we have demonstrated that APRc is sufficient to catalyze the in vitro processing of two conserved high molecular weight autotransporter adhesin/invasion proteins, Sca5/rOmpB and Sca0/rOmpA, thereby suggesting the participation of this enzyme in a relevant proteolytic pathway in rickettsial virulence. As a novel bona fide member of the retropepsin family of aspartic proteases, APRc emerges as an intriguing target for therapeutic intervention against fatal rickettsioses. Finally, with this work we demonstrate that retropepsin-type aspartic proteases are indeed present in gram-negative intracellular bacteria such as Rickettsia, suggesting that these enzymes may represent an ancestral form of this class of proteases.
FCT - SFRH/BD/47638/2008
Shityakov, Sergey. "Molecular modelling and simulation of retroviral proteins and nanobiocomposites." Doctoral thesis, 2011. https://nbn-resolving.org/urn:nbn:de:bvb:20-opus-56960.
Повний текст джерелаMolekulare Modellierung und Simulationen sind leistungsstarke Methoden, um wich-tige Informationen von verschiedenen biologischen Systemen, welche nicht durch Experi-mente erschlossen werden können, darzustellen, und deren strukturelle und funktionelle Ei-genschaften aufzuklären. Diese Arbeit untersucht in Simulationen Interaktionen viraler Proteinen sowie von Kohlenstoffenanoröhren mit Membranen und Proteinen. Die HIV-1 Integrase besitzt Kernlokalisierungssignale („nuclear localization signals [NLS]“), welche eine entscheidende Rolle beim Import des viralen Präintegrationskomplexes („preintegration complex [PIC]“) in den Zellkern spielen. Die Ausbildung des PIC und sein Import in den Zellkern sind im Detail noch nicht bekannt. Es wurde bereits gezeigt, dass die NLS an Moleküle des Zelltransportsystems binden, wie z.B. an Transportinkernporen. Im Rahmen meiner Arbeit untersuchte ich die Interaktionen der viralen HIV-1 Integrase mit Proteinen der Kernporen wie dem Transportin-SR2 Protein (Shityakov et al., 2010). Hierbei wurden die möglichen Interaktionen des Transportin-SR2 Protein mit der HIV-1-Integrase und die Bedeutung dieser Interaktionen mit dem Import in den Kern aufgezeigt. Zudem wur-den die Interaktionen der Schlüsseldomänen und die Ausbildung von Wasserstoffbrücken-bindungen im dem Transportin-SR2 Protein untersucht. Die Ergebnisse wurden mit Protein-komplexen andere retroviralen Spezies, wie z.B. dem humanen Spumaretrovirus („human foamy virus [HFV]“), verglichen, um diesen spezifischen und sehr effizienten retroviralen Transportweg in die Wirtszelle zu entschlüsseln. Der experimentelle Teil dieser Arbeit beschäftigte sich damit, den retroviralen Kern-import zu untersuchen, um die Fähigkeit des Retrovirus, nicht teilende Zellen zu infizieren, besser zu verstehen verstanden wird. Um dies zu bewerkstelligen, müssen Retroviren Zellkul-turen in verschiedenen Stadien des Zellzyklus effizient transduzieren. Vielversprechende und sichere- HFV- Vektoren, welche in der Gentherapie eingesetzt werden könnten, sind nicht in der Lage, diese Effizienz bei ruhenden Zellen zu gewährleisten. Dies rührte daher, dass diese nicht in der Lage waren, einen PIC für den Transport der retroviralen DNA auszubilden. Lentivirale Vektoren sind dagegen nicht auf einen bestimmten Zellzyklus angewiesen. Für die reverse Transkription ist der Polypurinteil („polypurine tract [PPT]“) essentiell für die Ausbildung der PIC. In dieser Doktorarbeit vergleiche ich die Transduktionsfrequenz von PPT-modifizierten HFV-Vektoren mit denen von lentiviralen Vektoren in nichtteilenden und tei-lenden Lungenkarzinomepithelzellen. Hierbei wurden Methoden wie Klonierung, Transfektion, und Transduktion (wie auch weitere Methoden) angewendet. Im Gegensatz zu lentiviralen Vektoren konnten HFV-Vektoren sich nicht teilende Zellen in meinen Versuchen nicht effizient transduzieren (Shityakov und Rethwiln, unveröffentlicht). Trotz der Befunde, dass HFV-Vektoren sichere und effiziente Alternativen zu lentiviralen Vektoren darstellen, bestehen immer noch große Einschränkungen, diese HFV-basierten, retroviralen Vektoren für Gentherapien bei ruhenden Zellen einzusetzen. Viele Versuche wurden unternommen, um mögliche, vielversprechende Moleküle, welche als Wirkstoffe für eine HIV-Therapie eingesetzt werden könnten, zu finden. Diese Moleküle können aus chemischen Substanzbibliotheken bezogen werden oder am Computer in silico entworfen und dann synthetisiert werden. Digitalisierte Strukturen können als Refe-renzen benutzt werden, um besser herauszufinden, wie diese Moleküle Typen diverse Enzy-me blokieren könnten. Strukturbasiertes Wirkstoffdesign hat das Potential, viele Jahre und Geld an Entwicklungskosten einzusparen. Nachdem die Kristallstruktur der HIV-kodierten Proteasen aufgeklärt war, spielte das computergestützte Wirkstoffdesign eine zentrale Rolle bei der Entwicklung neuer Wirkstoffe gegen die Protease. Vielversprechende Vertreter dieser Wirkstoffklasse werden seit kurzem nun auch für die Behandlung von Patienten eingesetzt. Proteaseinhibitoren zeigen eine wir-kungsvolle und langanhaltende Inhibition der HIV-1-Replikation; besonders dann, wenn sie in Kombinationstherapien eingesetzt werden. Aber diese Wirkstoffe werden immer weniger effektiv, je resistenter die HIV-Stämme durch Mutationen in den retroviralen Proteasen wer-den. Im Rahmen meiner Arbeit mit computergestütztem Wirkstoffdesign nutzte ich Model-lierungsmethoden wie den „lead expansion algorithm“ (Tripos®) um virtuelle Wirkstoffbibli-otheken mit verschiedenen Affinitäten zur Proteasebindungsstelle zu erstellen. Zusätzlich wandte ich Verfahren der computergestützten, kombinatorischen Chemie an, um virtuelle Bibliotheken von Proteaseinhibitoren zu designen, und zu verbessern. Parallel dazu wurde eine in silico Selektion sowie eine Einteilung nach Pharmakophorähnlichkeiten für diese Kandidaten vorgenommen. Weiterführende computergestützte Analysen förderten einen ein-zigartigen Wirkstoff zu Tage, welcher neuartige Proteasebindungseigenschaften aufweist, und dessen Rolle für eine potentiell neuartige Klasse von Proteaseinhibitoren schon beschrieben wurde (Shityakov und Dandekar, 2009). Eine Reihe von Modellen mit atomarer Auflösung wurden bereits entwickelt, um das Verhalten von Nanoröhren in Lipid-Doppelschichten aufzuklären. Die Auswirkungen auf die molekular Dynamik einer einschichtigen Karbonnanoröhre, welche in das Zentrum einer Lipid-Doppelschicht eingefügt wurde, wurden intensiv studiert und analysiert. Die Normalabweichung und Fluktuationen wurden berechnet, um eine Aussage über die Stabilität der Lipid-Doppelschichten treffen zu können. Die Ergebnisse weisen darauf hin, dass eine eingefügte Karbonnanoröhre die Freiheit für Konformationsänderungen bei nahegelegenen Lipiden einschränkt und dadurch einen Einfluss auf die Membranstabilität hat (Shityakov und Dandekar, 2011). Es kann aber außer-dem sein, dass verschiedene Lipid-Doppelschichten Unterschiede in ihrer Fähigkeit, Brücken zwischen benachbarten Lipiden auszubilden, aufweisen. Viren und Karbonnanoröhren werden damit in verschiedenen dynamischen Simulati-onen untersucht, um mehr über ihre Interaktionen mit Proteinen und Membranen zu erfahren
Schucht, Roland [Verfasser]. "Entwicklung von flexiblen Zelllinien für die Produktion rekombinanter Proteine und Retroviren / von Roland Schucht." 2006. http://d-nb.info/982016700/34.
Повний текст джерелаRold, Christopher James. "The role of the cellular proteasome and ubiquitin in post-entry restriction of retroviruses by TRIM5[alpha]." Diss., 2009. http://etd.library.vanderbilt.edu/available/etd-03302009-150129/.
Повний текст джерелаSantos, Andreia Sofia M. 1980. "Efeitos metabólicos associados à terapêutica anti-retroviral na infecção por VIH-1 : a experiência de utilização do atazanavir na prática clínica." Master's thesis, 2009. http://hdl.handle.net/10451/1048.
Повний текст джерелаThe lipid profile of individuals infected with HIV-1 is characterized with high levels of total cholesterol, LDL cholesterol and triglycerides e low levels of HDL cholesterol. The regimens based in atazanavir (ATV) revealed improved metabolic and lipid profile in comparison with other protease inhibitors, with identical viral suppression. The objectives of this study were to analyse the efficacy and safety of boosted ATV as part of combination antiretroviral therapy in HIV-1 infected patients. Study sample consisted of patients medicated with ATV/RTV at least for 6 months. Patients were recruited at the Infectious Diseases Department of Santa Maria Hospital in Lisbon. Clinical files were analyzed, including demographic, clinical, and laboratory data, as well as history of present and past therapy. Data from 190 patients was collected and analyzed in five different moments: before treatment with ATV/RTV, and at month 6, 12, 18, and 24. Safety of ATV/RTV was evaluated in terms of lipid and metabolic profile improvements, whereas the efficacy was established through HIV-1 viral load, and levels of T CD4+ cells. The use of ATV/RTV therapy was associated with no alteration in metabolic and lipid profile, meaning that this therapy does not increase the levels of total cholesterol, LDL, triglycerides and glycemia. The improved lipid and metabolic profile can reduce the cardiovascular risk and the metabolic complications of the patients doing this type of therapy. The efficacy was accomplished with a statistical significant reduction in viral load and a significant increase in CD4+ T cell counts.
Resumo alargado em português
Brand, Isabel [Verfasser]. "Charakterisierung der Interaktion zwischen dem tumorassoziierten Protein Np9 des humanen endogenen Retrovirus HERV-K (HML-2) und der humanen Serin-Protease (HumHtrA2) / eingereicht von Isabel Brand." 2006. http://d-nb.info/979353041/34.
Повний текст джерела